Business · 21/09/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Semprex SUPTM-D Capsules
Summary
The FDA has published a notice determining the regulatory review period for Semprex SUPTM-D Capsules, following a patent extension application submitted to the US Patent and Trademark Office.
Original source language: Federal Register — Health and Human ServicesOpen original release →